Recent U.S. Customs and Border Protection rulings from CROSS, searchable by HTS code, keyword, or ruling number.
In your letter dated November 3, 2025, on behalf of Chunghwa Chemical Synthesis & Biotech Co. Ltd., you requested a tariff classification ruling. Biolimus is a derivative of Sirolimus, and an inhibitor of mTOR (Mammalian target of rapamycin). It is an immunosuppressant drug and it is also known as Umirolimus (INN). In your letter, you stated that Biolimus is an anti-proliferative drug used in drug-eluting coronary stents to prevent restenosis.
Source: rulings.cbp.gov (CROSS). This index holds New York rulings from the recent period and the Headquarters rulings they cite. It is not the full CROSS database of 222,467 rulings, and it does not hold every Headquarters ruling. New rulings usually appear here within a few days of CBP publishing them; a ruling published long after its number was assigned can take several weeks. Revoked, modified and proposed marks come from the weekly Customs Bulletin, where CBP publishes most such actions under 19 U.S.C. 1625(c), read here from the Nov 2024 issues onward, and from the subjects of indexed Headquarters rulings. A revocation is marked from the date it takes effect. The absence of a mark is not confirmation that a ruling is still in effect. A ruling letter is binding on CBP only for the particular transaction or issue it describes (19 CFR 177.9). Confirm the text and status on CROSS before relying on a ruling. Not legal advice.